A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

NCT00637273 · Completed

Last updated 2026-05-28

This study compared the effects of a weekly injection of exenatide to two oral medications, sitagliptin and pioglitazone, in adults with type 2 diabetes who were already taking metformin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 514 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-01 · est. completion 2009-07

Where 62 sites · India, Mexico, United States

What this study is testing ClinicalTrials.gov NCT00637273 ↗

Description as written by the study sponsor.

This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.

Treatments tested

exenatide once weekly Drug

subcutaneous injection, 2.0mg, once a week
sitagliptin also known as Januvia Drug

oral tablet, 100mg, once a day
pioglitazone Drug

oral tablet, 45mg, once a day
placebo tablet Drug

oral tablet, once a day
placebo once weekly Drug

subcutaneous injection, once a week

Main thing measured	Change in HbA1c From Baseline to Week 26
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00637273 ↗